ArticleJournal of patient-reported outcomes2026
Longitudinal comparison of ePRO satisfaction ratings in patients with cancer receiving systemic or radiotherapy.
Article in Journal of patient-reported outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundePROs implementation for patients in active treatment for cancer requires that the app be nonburdensome and that it does not incumber clinical care team (CCT) workflows. Therefore, comparing longitudinal patient satisfaction of a single solution for those receiving radiation therapy (RT) and systemic therapies (ST; chemo-, immuno-, and hormonal) is critical to ensuring that maximal clinical benefit can be achieved with minimal impact to the provision of care. METHODOLOGY: Active treatment ePRO users with working active accounts > 30 days, who answered the question “How likely are you to recommend (software name) to another patient” using an 11-point scale twice or more (n = 7,202), were included. At a minimum all participants had access to three features: 1) symptom-reporting (administered at specific intervals or ad-hoc) via CTCAE-derived questionnaires or health-related quality of life questionnaires, 2) a diary to record any personal information, and 3) a secure communication feature for corresponding with the CCT. Additional data were passively collected by the app. All variables were analyzed descriptively and via a negative binomial mixed model (NB) with patient as a random effect and repeated measurements with an autoregressive covariance structure.
resultsPatients (mean age=61.7 years, SD=11.8) were from the US (n=4,941; sites=12), Canada (n=1,700; sites=4) and Europe (n=561; sites=4). Additionally, most were English speakers (n=6,794; 94.3%), used a smartphone (n=5,480; 76.1%), and received systemic therapy (n=6,468; 89.8%). The mean number of app satisfaction reports per patient was 3.1 (SD=1.6; range 2-13). The mean rating at Time 1 was 8.5 (SD=2.5), which is high, and it increased slightly over time. The NB mixed model found that satisfaction levels for patients receiving radiation did not significantly differ (p=0.835) from those receiving systemic therapy after adjusting for the other variables indicating that, over time, patients regardless of the treatment reported similar app satisfaction scores.
conclusionThese findings suggest that a single ePRO solution can be deployed with similarly high levels of patient satisfaction across two widely used treatment modalities, despite health system, practice, and ePRO deployment differences, minimizing CCT workflow and patient burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.